We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Company to host conference call and webcast today at 8:00 a.m. ET--MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc.

The celebrated actress has lost more than 100Ib after turning to controversial diabetes jab Ozempic - now better known for its impact on tackling obesity ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...